ReviewFrontiers in microbiology2026
From dysbiosis to tumorigenesis: microbiome-derived metabolites as emerging cancer biomarkers.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiome constitutes a complex and metabolically active ecosystem that exerts profound effects on host physiology through the production of diverse small-molecule metabolites. Increasing evidence indicates that microbiome-derived metabolites function as a critical bridge linking microbial dysbiosis with tumor initiation, progression, immune modulation, and therapeutic responsiveness. Alterations in microbial metabolic outputs, including short-chain fatty acids, secondary bile acids, polyamines, indole derivatives, and other bioactive compounds, can influence epithelial barrier integrity, inflammatory signaling, epigenetic regulation, and genomic stability within the tumor microenvironment. These metabolites serve as functional intermediaries in host-microbe communication and may contribute to systemic metabolic and immunological changes that support tumorigenesis across multiple malignancies. Notably, many microbiome-associated metabolites are detectable in accessible biological matrices such as stool, blood, and urine, highlighting their potential utility as minimally invasive biomarkers for cancer risk screening, diagnosis, and prognosis. Recent advances in high-throughput sequencing, metabolomics, and multi-omics integration have enabled comprehensive characterization of microbial metabolic networks associated with cancer development. In this review, we synthesize current insights into the functional diversity of microbiome-derived metabolites and their mechanistic roles in tumor biology. We further examine analytical platforms used for metabolite profiling and discuss emerging strategies for microbiome-targeted therapeutic modulation. Finally, we outline current methodological challenges and research priorities necessary for translating microbiome-metabolite interactions into clinically actionable frameworks for precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.